An experimental Alzheimer's vaccine just cleared a key early hurdle. AV-1959R, developed by Nuravax and the Institute for Molecular Medicine, triggered anti-amyloid-beta antibodies in all 12 vaccinated participants in a phase 1 trial — while none of the 4 placebo recipients showed any response. A phase 2 trial in people with confirmed amyloid pathology is now in the works.
An investigational Alzheimer's vaccine is showing early promise. AV-1959R, developed by Nuravax and the Institute for Molecular Medicine (IMM), successfully induced anti-amyloid-beta antibodies in every one of the 12 vaccinated participants in a 16-person, placebo-controlled phase 1 trial. The results, published in Molecular Neurodegeneration, mark the first clinical evidence that the vaccine's MultiTEP platform can overcome immune tolerance — a longstanding challenge in targeting amyloid-beta, a protein the body normally doesn't attack.
The vaccine's antibodies showed the strongest binding to aggregated amyloid-beta species (protofibrils and fibrils) — the forms most associated with Alzheimer's disease — and also bound amyloid plaques in cortical tissue from AD patients but not in healthy controls. Antibody modeling suggests titers could remain elevated for roughly a year after the initial two-dose priming series, supporting the case for an annual booster.
By the Numbers:
Why it matters: While the trial was too small to assess clinical efficacy or fully characterize safety, it clears a critical immunogenicity bar. A phase 2 trial in cognitively unimpaired adults with confirmed amyloid pathology is planned, with expanded safety monitoring and biomarker-based efficacy endpoints — a meaningful step toward a preventive Alzheimer's vaccine.
